Rechallenge with Anti-EGFR Therapy in Metastatic Colorectal Cancer (mCRC): Results from South Australia mCRC Registry
ConclusionsAnti-EGFR rechallenge provides clinical benefit in patients withRAS wild-type metastatic CRC.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
More News: Australia Health | Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Databases & Libraries | Erbitux | Study